Sign In
Buy FLXN
$25.10
-0.0069 (-0.0275%)
At Close: Jun 22, 2026
Guggenheim Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces Price Target of $20
10:00am, Wednesday, 27'th May 2020Flexion Therapeutics Inc (FLXN) President and CEO Michael D. Clayman Bought $99,996 of Shares
12:00am, Wednesday, 27'th May 2020Planning For A Rebound In Flexion Therapeutics (NASDAQ:FLXN)
07:39pm, Saturday, 23'rd May 2020
Today, we revisit biopharma Flexion Therapeutics. The company has had a tough 2020 so far, as a promising roll out of Zilretta has been sideswiped by the COVID-
Why Flexion Therapeutics Is Tumbling 10% Today
04:02pm, Thursday, 21'st May 2020
After the company reported it had priced its common share offering at $9.75 per share, shares in Flexion Therapeutics (NASDAQ: FLXN) are trading 10% lower at 11:30 a.m. EST on Thursday. Demand for t
Flexion Therapeutics Prices ~9.23M Shares At $9.75/Share
11:31am, Thursday, 21'st May 2020Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
11:30am, Thursday, 21'st May 2020
Flexion Therapeutics, Inc. (FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a price to the public of $9.75 per share. The gross proceed
Top Pharmaceutical Company Visionaries to Keynote Veeva Summit Online
12:00am, Thursday, 21'st May 2020
Alnylam and Pfizer to discuss how innovative oncology and specialty medicines are transforming commercial models and helping improve patients' lives
Flexion Therapeutics Announces A $75M Common Stock Offering
08:02pm, Wednesday, 20'th May 2020Flexion Therapeutics Announces Proposed Public Offering of Common Stock
08:01pm, Wednesday, 20'th May 2020
Flexion Therapeutics, Inc. (FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. Flexion also expects to grant the underwriters a
How Flexion Therapeutics (FLXN) Stock Stands Out in a Strong Industry
01:27pm, Thursday, 14'th May 2020
Flexion Therapeutics (FLXN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference
09:00pm, Wednesday, 13'th May 2020
BURLINGTON, Mass., May 13, 2020 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate.
Flexion Therapeutics to Present at the RBC Capital Markets —…—… Virtual Global ...
12:00am, Wednesday, 13'th May 2020Flexion Therapeutics Inc (FLXN) Q1 2020 Earnings Call Transcript
07:00pm, Saturday, 09'th May 2020
This is Scott Young, Vice President of Corporate Communications and Investor Relations. Today's conference call will be led by Flexion's Chief Executive Officer, Dr. Michael Clayman; and he is joined
